Congress tightens biotech export controls to block China access to genetic blueprints

What it does

This bill requires the U.S. government to issue export licenses for synthetic DNA and RNA sequences being sent to foreign entities in countries deemed adversarial (primarily China). It aims to prevent hostile governments and their proxies from obtaining genetic blueprints that could be used for military, surveillance, or bioweapon development. The bill empowers the Secretary of Commerce to enforce these controls within one year.

Why we flagged it

The bill's operative mechanism is a licensing requirement for exports of synthetic DNA/RNA sequences to adversarial foreign entities. It is a targeted national security measure, not a subsidy, deregulation, or commemorative act.

What the text implies

• The bill delegates substantial discretion to the Secretary of Commerce to define 'foreign entities of concern' and enforce licensing, potentially creating administrative burden on U.S. biotech companies and researchers seeking to collaborate internationally.
• The one-year implementation timeline may create compliance uncertainty for biotech firms and academic institutions that currently export or share synthetic sequences with international partners, even non-adversarial ones.
• The definition of 'digital sequence' is broad and may capture routine research data, educational materials, and published scientific findings, creating ambiguity about what constitutes a licensable export.
• The bill's reliance on the 'foreign country of concern' definition from the R&D Competition Act means the list of restricted countries could expand or contract based on executive branch determinations, creating regulatory volatility.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill restricts government-authorized exports of sensitive biological information to hostile foreign entities, protecting U.S. biotech intellectual property and reducing the risk that adversarial states could weaponize stolen genetic designs. Citizens benefit from reduced national security vulnerability and preserved competitive advantage in biotechnology.

Who stands to gain

• U.S. biotechnology and synthetic biology companies (protected from IP theft and foreign competition)
• U.S. pharmaceutical and biodefense contractors (reduced risk of adversarial biotech advancement)

Named in the bill

Secretary of Commerce, People's Republic of China, Export Control Reform Act of 2018, Research and Development, Competition, and Innovation Act, Export Administration Regulations, U.S. biotech and synthetic biology sector

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

• Dec 11, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Dec 11, 2025 — Referred to Senate Committee on Banking, Housing, and Urban Affairs · Congress.gov: “Read twice and referred to the Committee on Banking, Housing, and Urban Affairs”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 4 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $10,772,500 in lobbying spend. A filing names 52 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Tom Cotton, the sponsor, reported $1,292,206 in PAC receipts in the 2026 cycle. $1,000 of that came from 1 PAC tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Twist Bioscience Corporation — $82,500 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.